This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Keyword Search

Keyword Search Criteria: multiplicity returned 15 record(s)
Sunday, 08/01/2010
The Use and Misuse of Statistical Methods Reported in Clinical Cancer Research
Diane Liu, MD Anderson Cancer Center; J. Jack Lee, MD Anderson Cancer Center
2:20 PM

Monday, 08/02/2010
Evaluating personalized treatment strategies: Subset analyses do not avoid the loss of power due to subgroups with no treatment effect
Werner Vach, Institute of Medical Biometry and Medical Informatics; Rene dePont Christensen, University of Southern Denmark; Oke Gerke, Odense University Hospital
8:55 AM

Overcoming the Winner's Curse to Identify Biomarkers with Clinical Relevance in Drug Development
Lei Shen, Eli Lilly and Company; Haoda Fu, Eli Lilly and Company
3:20 PM

Tuesday, 08/03/2010
Evaluating Cardiovascular Risk in Diabetes Clinical Trials: Lessons Learned from Saxagliptin
J Mark Donovan, Bristol-Myers Squibb
10:35 AM

Multiplicity Issues in Meta-Analyses to Rule Out an Unacceptable Cardiovascular Risk
Stefan Hantel, Boehringer Ingelheim Pharmaceuticals, Inc.
10:55 AM

Model Prior Choice and Multiplicity Correction in Bayesian Model and Variable Selection
Melanie Ann Wilson, Duke University; Merlise Clyde, Duke University; Edwin Iversen, Duke University
11:15 AM

On Optimal Grouping Strategies Using Parallel Gatekeeping Procedures
Haiyuan Zhu, Forest Research Institute
3:20 PM

A Multiplicity Strategy Incorporating Fixed Sequential, Hochberg, and Fallback Procedures
Duane Snavely, Merck & Co., Inc.; Kenneth Liu, Merck & Co., Inc.
3:35 PM

Wednesday, 08/04/2010
Multiplicity Adjustment in Clinical Trials
Annpey Pong, Merck & Co., Inc.


Multiplicity Issues in Multidomain Patient Reported Outcome (PRO)--Based Endpoints
Mahboob Sobhan, FDA


Nonparametric Weighted Step Down Holm Method with Heteroscedastic Variables
Luigi Salmaso, University of Padova
9:15 AM

Thursday, 08/05/2010
Regulatory Considerations for Addressing Multiplicity Problems of Clinical Trials with Multiple Endpoints
Mohammad F. Huque, FDA
10:35 AM

Industry Perspective on the FDA Guidance on Multiplicity Issues
Walter W. Offen, Eli Lilly and Company
11:00 AM

Variations of and Types of Statistical Control for Multiplicity in Clinical Trials: The Academic Perspective
Joseph Massaro, Boston University; Ralph B. D'Agostino, Sr., Boston University
11:25 AM

Multiplicity in Clinical Trials: A European Perspective
Norbert Benda, BfArM; Joachim Roehmel , Institute for Prevention Research and Social Medicine
11:50 AM




2010 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.